Tingal, Jovie R.
HRN: 23-74-28 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/25/2023
CEFUROXIME 1.5GM (VIAL)
10/25/2023
10/26/2023
IV
1.5gm 3 Doses
Q8
Post CS
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueIntra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes